Periodontitis Inflammation
Conditions
Interventions
This is a planned, controlled, two-arm clinical trial with a parallel-group design and a single-blind approach regarding the researcher performing data collection (masking). Participants (n=40) will b
Sponsors
Universidade de São Paulo
Universidade de São Paulo
Eligibility
Age
30 Years to No maximum
Inclusion criteria
Inclusion criteria: Systemically healthy individuals; aged 30 years or older; both sexes; with at least 15 teeth present; at least 30% of the teeth presenting probing depth (PD) and clinical attachment loss (CAL) greater than or equal to 5 mm; individuals diagnosed with generalized Stage III or IV, Grade B or C periodontitis; excluding third molars and teeth indicated for extraction; presence of at least 8 teeth with at least one non-contiguous interproximal site presenting probing depth (PD) and clinical attachment level (CAL) greater than or equal to 5 mm
Exclusion criteria
Exclusion criteria: Completely edentulous individuals; current smokers or former smokers who quit within the past 5 years; pregnant or breastfeeding women; history of periodontal treatment within the previous 6 months; continuous use of oral antiseptics; use of systemic antibiotics, corticosteroids, nonsteroidal anti-inflammatory drugs, immunosuppressive agents, estrogen, selective estrogen receptor modulators, or medications that may affect bone metabolism (such as alendronate, calcitonin, and others) within the previous 6 months; presence of systemic conditions that may alter the host response to periodontal treatment (such as diabetes, human papillomavirus infection, or Down syndrome) or that require antibiotic prophylaxis before dental treatment (such as mitral valve prolapse); use of probiotics within the previous 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to identify changes in periodontal parameters (full periodontal charting) by comparing the test and control groups 90 days after the completion of scaling and root planing, and the influence of probiotic use on the assessed parameters. | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to observe an improvement in the immunoinflammatory profile of participants through the quantification of inflammatory and immunological biomarkers in biological samples from gingival crevicular fluid, using immunoenzymatic assays (Luminex), including pro- and anti-inflammatory cytokines (IL-6, TNF-a, IFN-?, IL-10, IL-1ß, IL-8), aiming to analyze the influence of periodontal therapy associated with probiotic use on these markers. | — |
Countries
BR
Contacts
Public ContactMichel Messora
Faculdade de Odontologia de Ribeirão Preto - Universidade de São Paulo
Outcome results
None listed